Management of Children With or Exposed to HIV

  • Authors: James A. McAuley, MD, MPH; Mariam Aziz, MD (More Info)
  • Associate Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/12/18 (What's New)

Summary

  • Infants diagnosed with HIV infection while receiving antiretroviral prophylaxis for the prevention of mother-to-child transmission should stop prophylactic therapy and initiate fully active combination ART (Management Guidelines)[DHHS Pediatric]
  • More than 20 antiretrovirals have FDA approval for use in children; 16 are available as liquids or chewable tablets (Table 2)
  • DHHS and WHO guidelines recommend lopinavir/ritonavir plus 2 NRTIs as a preferred initial therapy for children 14 days of age or older to younger than 3 years of age[DHHS Pediatric; WHO ART]

    Action required

    Keywords: Initial Antiretroviral Therapy, Pediatric/Adolescent Patients, Pediatric/Adolescent Patients , Resistance Testing

    ©2018 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.